February 8, 2021 -- Illumina picked nine genomics companies to join the second global funding cycle of the Illumina Accelerator in the U.S. and U.K.
The firm announced more than 20 million pounds ($27.5 million U.S.) in initial U.K. capital commitments, including a 10 million pound ($13.8 million) commitment from the U.K. medical research charity LifeArc. The U.K. commitments will provide pound-for-pound match funding to every Illumina Accelerator Cambridge or San Francisco Bay Area graduate that secures between 500,000 pounds ($687,550) and 4 million pounds ($5.5 million) in qualified new capital within one year of graduation.
The nine companies are the following:
- BiotaX Labs
- Broken String Biosciences
- Mitra Bio
- MultiplAI Health
- Doloromics
- Flightpath Biosciences
- Oshun Medical
- Parallel Health
- Rubik Therapeutics
Illumina Accelerator is accepting applications for the next funding cycle, due March 1.
Copyright © 2021 scienceboard.net